Results 101 to 110 of about 78,778 (305)
OPPORTUNITIES OF FLOW CYTOMETRY IN DIAGNOSTICS OF INFECTIOUS DISEASES. Part 2
. Flow cytometry allows estimating quantitative and qualitative structure of populations and subpopulations of immune system cells by using various methodical approaches and a wide spectrum of reagents.
S. V. Khaidukov, A. V. Zurochka
doaj +1 more source
Objective Still disease (SD) is an autoinflammatory disorder characterized by remarkably high interleukin‐18 (IL‐18) levels. Increasing evidence suggests that adaptive immunity also contributes to its pathogenesis, particularly in refractory courses. Macrophage activation syndrome (MAS), one of SD's most severe complications, is associated with further
Greta Rogani +17 more
wiley +1 more source
Objective Sjögren's disease (SjD) is a heterogeneous autoimmune disorder characterized by substantial clinical and molecular diversity. This heterogeneity raises key questions regarding the existence of distinct pathogenic mechanisms underlying disease subtypes.
Geoffrey Urbanski +15 more
wiley +1 more source
Objective: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of non-Hodgkin lymphomas (NHLs) often sub-classified into major germinal centre (GC) and activated B-cell (ABC) cell-of-origin types.
Elizabeth J Soilleux +8 more
doaj +1 more source
While chronic inflammation has been causally associated with several epithelial malignancies, whether it causally contributes to the development of prostate cancer has remained unclear.
Preston D. Crowell, Andrew S. Goldstein
doaj +1 more source
CD38 as theranostic target in oncology
CD38 is a multifunctional transmembrane glycoprotein found in multiple tissues and overexpressed in many cancer cells, notably in hematological malignancies such as leukemia and multiple myeloma (MM). Therefore, targeting CD38 remains an attractive strategy for cancer treatment in hematological malignancies as well as in solid tumors.
Valentina Bocuzzi +7 more
openaire +4 more sources
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
Expression of plasma cell markers in colon cancer and lung adenocarcinoma
Certain clusters of differentiation that are markers of plasma cells (CD38 and CD138) can be expressed not only on plasma cells infiltrating the tumor and its microenvironment, but also on the tumor cells themselves and in the stroma of malignant ...
S. A. Fursov +4 more
doaj +1 more source
Affinity Peptides With pH Sensitivity for the Enrichment of CD38+ Cells
ABSTRACT The selective enrichment of cell populations based on surface markers is critical for the advancement of gene and cell therapies. Current antibody‐based cell isolation methods, such as fluorescence‐ and magnetic‐activated cell sorting (FACS and MACS), offer high specificity but are limited by scalability, cost, and potential adverse effects on
Gabrielle Rusch +7 more
wiley +1 more source

